Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMOVE
2023-504946-70-00Phase 4Authorised
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Apr 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of eplerenone, valsartan, bisoprolol and furosemide in heart failure (HF), Non-Ischaemic Cardiomyopathy (NICM) and Left bundle branch block (LBBB), sponsored by Fundación para la Formación e Investigación Sanitaria. Primary endpoint: Relapse of cardiomyopathy after drug withdrawal. Planned start Apr 2023; status: authorised.
02
Drugs
eplerenonevalsartanbisoprololfurosemide
03
Conditions
heart failure (HF)Non-Ischaemic Cardiomyopathy (NICM)Left bundle branch block (LBBB)
Beyond the preview
Go deeper on 2023-504946-70-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504946-70-00.